Aclaris Therapeutics ACRS Licensing Expenses
Licensing Expenses at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept acrs:LicensingExpenses.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's licensing expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's licensing expenses?
- Aclaris Therapeutics (ACRS) reported licensing expenses of $1.39M in Q1 2026.
- How has Aclaris Therapeutics's licensing expenses changed year-over-year?
- Aclaris Therapeutics's licensing expenses increased by 37.9% year-over-year, from $1.01M to $1.39M.
- What is the long-term trend for Aclaris Therapeutics's licensing expenses?
- Over 2 years (2023 to 2025), Aclaris Therapeutics's licensing expenses has grown at a -40.5% compound annual growth rate (CAGR), from $14.66M to $5.19M.
- What does licensing expenses mean?
- Represents the costs incurred by the company to acquire, maintain, or renew intellectual property rights and technology licenses. These expenses are essential for securing the legal right to develop or commercialize specific drug candidates within the company's pipeline. Monitoring these costs helps investors assess the company's commitment to external innovation and the ongoing financial obligations associated with its therapeutic portfolio.